Physician profile
Mariah M Winningham
NPI 1164198073
$4,729.58
in general payments reported to CMS, 2019-2025
30 companies · $1,307 in 2025
The $1,307 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $201 · 2022: $810 · 2023: $1,028 · 2024: $1,384 · 2025: $1,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,717 · Education: $2.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,716.80 |
| Education | $2.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,166.06 | 2021-2025 | Lifevest |
| Edwards Lifesciences Corporation | $758.98 | 2024-2025 | Sapien 3 Ultra Resilia |
| Pfizer INC. | $531.32 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $357.51 | 2022-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $256.74 | 2021-2025 | Watchman Flx, Watchman, Watchman Access System |
| Merck Sharp & Dohme LLC | $180.53 | 2021-2025 | Verquvo |
| Cvrx, INC. | $174.39 | 2023-2024 | Barostim Neo System |
| Amgen INC. | $161.11 | 2021-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $155.19 | 2021-2025 | Wainua, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.70 | 2022-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $128.07 | 2022-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $115.07 | 2024 | Arcalyst |
| Novartis Pharmaceuticals Corporation | $72.56 | 2023 | |
| Amarin Pharma, INC. | $67.14 | 2022 | |
| Medtronic, INC. | $53.76 | 2021-2023 | Linq II |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $49.75 | 2024 | Impella |
| Actelion Pharmaceuticals US, INC. | $41.88 | 2023-2024 | Opsumit, Uptravi |
| Inspire Medical Systems, INC. | $39.27 | 2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $37.59 | 2024 | |
| Scpharmaceuticals INC. | $36.94 | 2024 | |
| Baxter Healthcare | $36.13 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Atricure, INC. | $35.47 | 2024 | |
| Alnylam Pharmaceuticals INC. | $34.66 | 2022 | |
| Philips North America LLC | $23.98 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Daiichi Sankyo INC. | $22.65 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.59 | 2022 | |
| Esperion Therapeutics, INC. | $15.76 | 2024 | Nexletol |
| Altathera Pharmaceuticals LLC | $15.05 | 2025 | Sotalol Hydrochloride |
| Cardiovascular Systems INC. | $12.73 | 2021 | |
| Vivaquant INC, Dba Rhythm Express | $4.00 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariah Winningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.